PRIMARY OBJECTIVES:~I. Reduce the rate of bacterobilia driven surgical site infection (SSI) in patients undergoing pancreatic head resection by providing surgical team with nanopore sequencing (NS) data in the post-operative setting.~II. Reduce cost of care through reduction in SSI and improved antibiotic stewardship.~OUTLINE: Patients are randomized to 1 of 2 arms.~ARM I: Patients undergo the collection of bile samples during standard of care surgery. Samples undergo routine laboratory testing.~ARM II: Patients undergo the collection of bile samples during standard of care surgery. Samples undergo nanopore sequencing and routine laboratory testing.~After completion of study, patients' medical records are reviewed for 30 days.
This early phase I trial evaluates nanopore sequencing for its ability to detect bacteria in bile and prevent surgical site infections in patients undergoing surgery for benign or malignant pancreatic tumors. Surgical site infections are a significant source of poor outcomes in patients undergoing surgery for pancreatic tumors. In most patients who develop this kind of infection, the bacteria identified as causing the infection is also frequently found to be in the bile at time of surgery. Using nanopore sequencing to detect bacteria in the bile of patients undergoing surgery may allow doctors to prevent surgical site infections or treat them sooner or more effectively.